Dr. Dan Weng
President, CEO
Dr. Dan Weng serves as President and Chief Executive Officer of Medelis. Dr. Weng has extensive experience managing and growing CROs, including nearly six years at EPS International Holding Co., a subsidiary of EPSH, where he was Chairman, President and CEO. During his tenure at EPS, Dr. Weng oversaw significant growth, organically and through M&A in Asia. He also had an active role in corporate strategy and investor relations.
Prior to Medelis and EPS, Dr. Weng had a track record of delivering growth in executive positions at international CROs including MedPace, Icon Clinical Research, PharmaNet and Quintiles, where he established the offering in China. Dr. Weng’s background covers multiple therapeutic areas, supporting all stages of development through approval. Dr. Weng qualified as a medical doctor at Tongji Medical University, China, and holds an MA in Health Planning, Policy and Management from the University of Leeds, UK. He also held research positions at Harvard Medical School, Massachusetts General Hospital and the University of California.